COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
amcure GmbH is a Karlsruhe Institute of Technology spin-off developing peptide-based CD44v6-targeting therapeutics, notably AMC303, which blocks VEGF/VEGFR-2, HGF/c-Met and MSP/RON signaling and is in Phase I/Ib clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors